{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:11:53Z","timestamp":1792800713943,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Several large, randomized clinical trials have tested the efficacy of adding behavioral therapy to medical management (high-quality, low-intensity medical counseling) and buprenorphine treatment of opioid use disorder. These studies have consistently reported strong rates of treatment response overall, without a significant additive benefit of additional behavioral therapy.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To address gaps in knowledge about additional behavioral therapy for patients receiving buprenorphine, including the association of additional behavioral therapy with retention and functional outcomes, and whether certain subgroups respond better to additional behavioral therapy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This study is a secondary analysis of 4 randomized clinical trials conducted in Connecticut, Southern California, and 10 other US sites between 2000 and 2011. Participants included adults with\n Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition)<\/jats:italic>\n opioid dependence. Analyses were conducted between January 2024 and July 2025.\n <\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Buprenorphine and varying levels of behavioral therapy, including standard medical management, physician management, physician management plus cognitive behavioral therapy, contingency management, contingency management plus cognitive behavioral therapy, standard medical management plus opioid dependence counseling, or no additional behavioral treatment.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcomes included weeks of buprenorphine retention and functioning across 7 domains (medical, employment and financial support, social and family, alcohol, drug, legal, and psychiatric), assessed using the Addiction Severity Index. Data on additional behavioral therapy (structured cognitive-behavioral and counseling approaches) combined with buprenorphine and medical management were harmonized to provide needed statistical power for considering moderation effects.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The combined sample consisted of 869 adults (mean [SD] age, 34.2 [10.4] years; 287 female [33%]). Results demonstrated that additional behavioral therapy was not associated with opioid-free weeks (mean [SD] number of opioid-free weeks, 7.16 [4.35]) compared with medical management and buprenorphine (mean [SD] number of opioid-free weeks, 7.00 [4.33]) (B\u2009=\u20090.28; 95% CI, \u22120.33 to 0.89;\n P<\/jats:italic>\n \u2009=\u2009.37). Additional behavioral therapy was also not associated with greater buprenorphine retention (mean [SD] number of weeks of buprenorphine, 10.29 [3.21] out of 12) compared with medical management and buprenorphine (mean [SD] number of weeks of buprenorphine, 10.21 [3.15]) (B\u2009=\u20090.00; 95% CI, \u22120.43 to 0.43;\n P<\/jats:italic>\n \u2009=\u2009.98). Measures of functioning indicated minimal change over the course of treatment, and there were no differences between randomized groups. No moderational effects of subgroups (eg, history of heroin use) were significant when correcting for multiple comparisons.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this secondary analysis of 4 randomized clinical trials, results highlighted the strong efficacy of buprenorphine treatment when combined with medical management for opioid use disorder. Although there was certainly room for improvement in outcomes\u2014particularly functioning\u2014trials of novel adjuncts for buprenorphine treatment may encounter statistical power challenges outperforming such a robust control condition.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n NCT00316277<\/jats:ext-link>\n ,\n NCT00591617<\/jats:ext-link>\n ,\n NCT00632151<\/jats:ext-link>\n ,\n NCT00023283<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.28529","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T15:00:27Z","timestamp":1755702027000},"page":"e2528529","source":"Crossref","is-referenced-by-count":4,"title":["Behavioral Therapy as an Adjunct to Buprenorphine Treatment for Opioid Use Disorder"],"prefix":"10.1001","volume":"8","author":[{"given":"R. Kathryn","family":"McHugh","sequence":"first","affiliation":[{"name":"Division of Alcohol, Drugs and Addiction, McLean Hospital, Belmont, Massachusetts"},{"name":"Department of Psychiatry, Harvard Medical School, Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen J.","family":"Bailey","sequence":"additional","affiliation":[{"name":"Division of Alcohol, Drugs and Addiction, McLean Hospital, Belmont, Massachusetts"},{"name":"Department of Psychiatry, Harvard Medical School, Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke A.","family":"McConaghy","sequence":"additional","affiliation":[{"name":"Division of Alcohol, Drugs and Addiction, McLean Hospital, Belmont, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Division of Alcohol, Drugs and Addiction, McLean Hospital, Belmont, Massachusetts"},{"name":"Department of Psychiatry, Harvard Medical School, Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Hillhouse","sequence":"additional","affiliation":[{"name":"Marron Institute, New York University, Brooklyn, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent A.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett M.","family":"Fitzmaurice","sequence":"additional","affiliation":[{"name":"Division of Alcohol, Drugs and Addiction, McLean Hospital, Belmont, Massachusetts"},{"name":"Department of Psychiatry, Harvard Medical School, Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"issue":"12","key":"zoi250800r1","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"zoi250800r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108774","article-title":"Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: patterns, predictors, and association with buprenorphine treatment outcomes.","volume":"139","author":"Samples","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"10118","key":"zoi250800r3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"zoi250800r4","doi-asserted-by":"publisher","first-page":"74.e11","DOI":"10.1016\/j.amjmed.2012.07.005","article-title":"A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.","volume":"126","author":"Fiellin","year":"2013","journal-title":"Am J Med"},{"issue":"10","key":"zoi250800r5","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/add.12266","article-title":"Comparison of behavioral treatment conditions in buprenorphine maintenance.","volume":"108","author":"Ling","year":"2013","journal-title":"Addiction"},{"issue":"4","key":"zoi250800r6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.","volume":"355","author":"Fiellin","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi250800r7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2024.3836","article-title":"Capturing the full range of buprenorphine treatment response.","volume":"82","author":"Bailey","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"zoi250800r8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/archpsyc.56.6.493","article-title":"Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse collaborative cocaine treatment study.","volume":"56","author":"Crits-Christoph","year":"1999","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"zoi250800r9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15288\/jsa.1997.58.7","article-title":"Matching alcoholism treatments to client heterogeneity: project MATCH posttreatment drinking outcomes.","volume":"58","year":"1997","journal-title":"J Stud Alcohol"},{"issue":"12","key":"zoi250800r10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1037\/ccp0000447","article-title":"A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition.","volume":"87","author":"Magill","year":"2019","journal-title":"J Consult Clin Psychol"},{"issue":"5","key":"zoi250800r11","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1037\/0022-006X.74.5.955","article-title":"The use of contingency management and motivational\/skills-building therapy to treat young adults with marijuana dependence.","volume":"74","author":"Carroll","year":"2006","journal-title":"J Consult Clin Psychol"},{"issue":"7","key":"zoi250800r12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1176\/appi.ajp.2008.07111835","article-title":"Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT.","volume":"165","author":"Carroll","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"4","key":"zoi250800r13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/01.jcp.0000172071.81258.04","article-title":"Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence.","volume":"25","author":"Anton","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"zoi250800r14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000086397","article-title":"Group psychotherapy for opiate addicts in methadone maintenance treatment\u2013a controlled trial.","volume":"11","author":"Scherbaum","year":"2005","journal-title":"Eur Addict Res"},{"issue":"2","key":"zoi250800r15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/08897077.2019.1569192","article-title":"Randomized pilot trial of web-based cognitive-behavioral therapy adapted for use in office-based buprenorphine maintenance.","volume":"40","author":"Shi","year":"2019","journal-title":"Subst Abus"},{"issue":"8","key":"zoi250800r17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","article-title":"The role of behavioral interventions in buprenorphine maintenance treatment: a review.","volume":"174","author":"Carroll","year":"2017","journal-title":"Am J Psychiatry"},{"key":"zoi250800r18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.drugalcdep.2014.04.005","article-title":"Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?","volume":"140","author":"Weiss","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi250800r19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11606-007-0129-0","article-title":"Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.","volume":"22","author":"Moore","year":"2007","journal-title":"J Gen Intern Med"},{"key":"zoi250800r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109084","article-title":"Do people with opioid use disorder and posttraumatic stress disorder benefit from adding individual opioid drug counseling to buprenorphine?","volume":"228","author":"McHugh","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi250800r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100226","article-title":"Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder.","volume":"11","author":"McHugh","year":"2024","journal-title":"Drug Alcohol Depend Rep"},{"issue":"1","key":"zoi250800r22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1521-0391.2009.00003.x","article-title":"The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine\/naloxone for the treatment of opioid dependence.","volume":"19","author":"Sullivan","year":"2010","journal-title":"Am J Addict"},{"issue":"1-2","key":"zoi250800r23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2012.12.010","article-title":"Patient characteristics associated with buprenorphine\/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.","volume":"131","author":"Dreifuss","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zoi250800r24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/ajad.12414","article-title":"Predictors of early dropout in outpatient buprenorphine\/naloxone treatment.","volume":"25","author":"Marcovitz","year":"2016","journal-title":"Am J Addict"},{"issue":"3","key":"zoi250800r27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the addiction severity index.","volume":"9","author":"McLellan","year":"1992","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"zoi250800r28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"3","key":"zoi250800r30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"The CES-D scale: a self-report depression scale for research in the general population.","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl Psychol Meas"},{"issue":"3","key":"zoi250800r32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R.","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"issue":"2","key":"zoi250800r34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1037\/a0035768","article-title":"Establishing a common metric for depressive symptoms: linking the BDI-II, CES-D, and PHQ-9 to PROMIS depression.","volume":"26","author":"Choi","year":"2014","journal-title":"Psychol Assess"},{"issue":"4","key":"zoi250800r35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1360-0443.2003.00665.x","article-title":"Studies of the reliability and validity of the Addiction Severity Index.","volume":"99","author":"M\u00e4kel\u00e4","year":"2004","journal-title":"Addiction"},{"issue":"1","key":"zoi250800r36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/add.14289","article-title":"What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?","volume":"114","author":"Kiluk","year":"2019","journal-title":"Addiction"},{"issue":"2","key":"zoi250800r37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pnpbp.2005.10.007","article-title":"Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study.","volume":"30","author":"Gerra","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"zoi250800r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54950","article-title":"Mindfulness training vs recovery support for opioid use, craving, and anxiety during buprenorphine treatment: a randomized clinical trial.","volume":"8","author":"Schuman-Olivier","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi250800r39","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/jamapsychiatry.2023.5138","article-title":"Telehealth mindfulness-oriented recovery enhancement vs usual care in individuals with opioid use disorder and pain: a randomized clinical trial.","volume":"81","author":"Cooperman","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"zoi250800r26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring Alcohol Consumption: Psychosocial and Biochemical Methods","author":"Sobell","year":"1992"},{"key":"zoi250800r29","volume-title":"Beck Depression Inventory-II","author":"Beck","year":"1996"},{"key":"zoi250800r33","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-21706-2","volume-title":"Modern Applied Statistics with S","author":"Venables","year":"2002","edition":"4th ed"},{"key":"zoi250800r16","unstructured":"National Academy of Sciences, Engineering, and Medicine Committee on Medication-Assisted Treatment for Opioid Use Disorder. Consensus report: medications for opioid use disorder save lives. Published 2019. Accessed July 17, 2025. https:\/\/www.careinnovations.org\/wp-content\/uploads\/MOUD-Saves-Lives_NAS_2019.pdf"},{"key":"zoi250800r25","doi-asserted-by":"crossref","unstructured":"Carroll? KM. A cognitive-behavioral approach: treating cocaine addiction. National Institute on Drug Abuse. Published April 1998. Accessed July 17, 2025. https:\/\/archives.nida.nih.gov\/sites\/default\/files\/cbt.pdf","DOI":"10.1037\/e722512007-001"},{"key":"zoi250800r31","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. 2024. Accessed July 17, 2025. https:\/\/www.R-project.org"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837787\/mchugh_2025_oi_250800_1755016718.27902.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T15:00:29Z","timestamp":1755702029000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837787"}},"subtitle":["A Secondary Analysis of 4 Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.28529","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}